A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 7,500 shares of VERV stock, worth $34,125. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,500
Previous 12,400 39.52%
Holding current value
$34,125
Previous $60,000 40.0%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.4 - $7.86 $1.05 Million - $1.87 Million
237,695 Added 46.85%
745,055 $3.61 Million
Q2 2024

Aug 14, 2024

SELL
$4.76 - $12.79 $3.19 Million - $8.57 Million
-669,725 Reduced 56.9%
507,360 $2.48 Million
Q1 2024

May 15, 2024

BUY
$10.81 - $17.96 $7.86 Million - $13.1 Million
727,265 Added 161.68%
1,177,085 $15.6 Million
Q4 2023

Feb 14, 2024

BUY
$8.84 - $18.7 $1.88 Million - $3.98 Million
212,617 Added 89.64%
449,820 $6.27 Million
Q3 2023

Nov 14, 2023

SELL
$11.42 - $20.82 $5.24 Million - $9.55 Million
-458,837 Reduced 65.92%
237,203 $3.15 Million
Q2 2023

Aug 14, 2023

BUY
$13.34 - $19.9 $3.62 Million - $5.4 Million
271,178 Added 63.83%
696,040 $13.1 Million
Q1 2023

May 15, 2023

BUY
$14.3 - $24.01 $5.55 Million - $9.32 Million
388,028 Added 1053.45%
424,862 $6.13 Million
Q4 2022

Feb 14, 2023

SELL
$17.85 - $40.7 $606,828 - $1.38 Million
-33,996 Reduced 48.0%
36,834 $712,000
Q3 2022

Nov 14, 2022

SELL
$15.63 - $41.49 $15.8 Million - $41.9 Million
-1,010,725 Reduced 93.45%
70,830 $2.43 Million

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $273M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.